Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BMY
BRISTOL-MYERS SQUIBB COMPANY
NYSE
$66.80
▼ DOWN 0.01% (-0.01)

KEY STATISTICS

Market Cap$136.62 B
52w High$68.64
52w Low$42.52
Dividend Yield4.51%
FrequencyQuarterly
P/E11.26
Volume4.01M
Shares Out.2.04B

COMPANY

LEADERSHIP

Christopher S. Boerner
CHIEF EXECUTIVE
Christopher S. Boerner

COMPENSATION 2026

Salary$1,586,346
Stock Awards$16,061,399
Incentive Plan Pay$3,754,684
All Other Comp.$477,490
Total$21,879,919

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 1, 1972
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
32,500

PRICE TARGET

Target High$75.00
Target Low$59.00
Target Median$70.00
Target Consensus$69.00

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$12.59B
OCT
29
THU

SPLIT RECORD

DATETYPERATIO
2001-08-07Forward1000000:951777
1999-03-01Forward2:1
1997-03-03Forward2:1
1987-06-10Forward2:1
1983-05-27Forward2:1
1977-05-31Forward2:1

PRICE

$66.80 ▼ DOWN 0.01% (−$0.01)
OVERLAYS
$66.80$67.20$67.60$68.009:30 AM10:33 AM11:36 AM12:39 PM1:42 PM2:45 PM3:48 PM66.80

About Bristol-Myers Squibb Company

https://www.bms.com ↗

Bristol-Myers Squibb is a global biopharmaceutical company developing and marketing medicines across hematology, oncology, cardiovascular, immunology, neuroscience, and COVID-19, serving diverse healthcare providers worldwide.

INDUSTRY

Drug Manufacturers - General

A PRODUCT BRISTOL-MYERS SQUIBB COMPANY IS KNOWN FOR

Opdualag (nivolumab and relatlimab-rmbw)
Opdualag (nivolumab and relatlimab-rmbw)

Opdualag, FDA-approved in 2022, is a first-in-class fixed-dose dual immunotherapy combining nivolumab and relatlimab for unresectable or metastatic melanoma, marking a significant advancement in treatment and a key growth product for Bristol-Myers...

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Eliquis$3.75B $3.45B ▼$4.14B ▲$4.48B ▲
Opdivo$2.53B $2.69B ▲$2.15B ▼$2.48B ▲
Orencia$964M $1.01B ▲$818M ▼$1.03B ▲
Yervoy$739M $809M ▲$651M ▼$769M ▲
Reblozyl$615M $666M ▲$555M ▼$735M ▲
Other Growth Brands$514M $537M ▲$581M ▲$653M ▲
Breyanzi$359M $392M ▲$411M ▲$484M ▲
Revlimid$575M $602M ▲$349M ▼$425M ▲
Camzyos$296M $353M ▲$314M ▼$416M ▲
Opdualag$299M $350M ▲$295M ▼$349M ▲
Opdivo Ovantig$67M $132M ▲$163M ▲$261M ▲
PomalystImnovid$675M $692M ▲$513M ▼$204M ▼
Other Legacy Brands$177M $199M ▲$156M ▼$170M ▲
Zeposia$161M $159M ▼$118M ▼$169M ▲
Abecma$137M $100M ▼— —
Sprycel$119M $79M ▼$73M ▼$88M ▲
Sotyktu$80M $86M ▲$69M ▼$87M ▲
Cobenfy$43M $50M ▲$56M ▲$63M ▲
Abraxane$74M $84M ▲$50M ▼$55M ▲
Krazati$53M $56M ▲$50M ▼$55M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$8.33B $8.56B ▲$7.79B ▼$8.99B ▲
Other Region$290M $309M ▲$257M ▼$318M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
1,216
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.18% · 65.0M
SCHD
3.31% · 55.8M
IHVV.AX
0.20% · 27.2M
SPY
0.20% · 25.0M
AFTY
5.97% · 11.0M
JEPI
0.80% · 5.5M
MOAT
2.54% · 4.7M
FDL
3.64% · 4.4M
RSP
0.22% · 3.4M
DUHP
0.94% · 1.8M
SMOR.SW
0.27% · 1.1M
RECS
1.14% · 1.0M
FHLC
1.87% · 979.8K
XDWH.L
1.59% · 968.5K
XZ
XZME.F
0.48% · 699.2K
DLN
0.71% · 679.7K
ZSP.TO
0.21% · 637.7K
GSLC
0.21% · 492.1K
SDOG
2.24% · 482.7K
PB
PBPH
2.99% · 463.0K
HMWD.L
0.15% · 419.8K
UETW.DE
0.15% · 388.0K
ABFL
2.63% · 385.1K
SPYI
0.21% · 364.9K
QDF
0.92% · 350.2K
AVUS
0.16% · 349.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
52.83%
HOLDERS
3,708
TOP 12 OF 3,708 · RANKED BY POSITION SIZE
Vanguard Group Inc
198.7M sh · $10.72B
Blackrock, Inc.
180.4M sh · $10.39B
Blackrock Inc.
158.7M sh · $6.59B
State Street Corp
102.4M sh · $5.9B
Jpmorgan Chase & Co
92.5M sh · $5.52B
Charles Schwab Investment Management Inc
73.0M sh · $3.29B
Sixth Street Partners Management Company, L.P.
67.6M sh · $3.89B
Geode Capital Management, LLC
56.4M sh · $3.24B
Blackrock Institutional Trust Company, N.A.
46.1M sh · $2.69B
Norges Bank
36.9M sh · $2.12B
Bank Of America Corp /De/
34.0M sh · $1.96B
Ameriprise Financial Inc
32.5M sh · $1.46B

RATINGS SNAPSHOT

Overall rating: A-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings2
Price To Book2
Overall Score4

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2025-12-19
 Julie Johnson
Julie Johnson
Sale
2025-12-18
 Ro Khanna
Ro Khanna
Sale
2025-09-29
 Virginia Foxx
Virginia Foxx
Sale
2025-06-24

INSIDER TRADES

★
OFFICER: SVP AND CONTROLLER
Holzer Phil M
Sale · 500 shares
2026-08-25
★
OFFICER: EVP, GENERAL COUNSEL
Gallman Cari
Purchase · 1.1K shares
2026-08-01
★
OFFICER: EVP,CHIEF MED OFFR,HEAD OF DEV
Massacesi Cristian
Sale · 51.2K shares
2026-08-01
★
OFFICER: EVP,CHIEF MED OFFR,HEAD OF DEV
Massacesi Cristian
Sale · 26.2K shares
2026-08-01

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
NEUTRAL 3
OVERWEIGHT 2
SECTOR PERFORM 2
EQUAL WEIGHT 1
HOLD 1
OUTPERFORM 1
UNDERWEIGHT 1
16 GRADES IN THE LAST 12 MONTHS
Argus Research BUY Citigroup NEUTRAL Wells Fargo EQUAL WEIGHT Cantor Fitzgerald NEUTRAL Guggenheim BUY JP Morgan OVERWEIGHT RBC Capital SECTOR PERFORM Truist Securities BUY

SECTORS PEERS

PEERPRICE
PFE$28.57COMPARE
VRTX$548.32COMPARE
CVS$96.77COMPARE
SNY$44.46COMPARE
MCK$910.24COMPARE
GSK$50.58COMPARE
HCA$417.54COMPARE
ELV$401.49COMPARE